

## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010

## **CHEK1 RABBIT PAB**

货号: S221730

产品全名: CHEKI 兔多抗

基因符号 CHK1

UNIPROT ID: 014757 (Gene Accession - NP\_001265)

背景: The protein encoded by this gene belongs to the Ser/Thr protein kinase family. It is required for checkpoint mediated cell cycle arrest in response to DNA damage or the presence of unreplicated DNA. This protein acts to integrate signals from ATM and ATR, two cell cycle proteins involved in DNA damage responses, that also associate with chromatin in meiotic prophase I. Phosphorylation of CDC25A protein phosphatase by this protein is required for cells to delay cell cycle progression in response to double-strand DNA breaks. Several alternatively spliced transcript variants have been found for this gene.

抗原: Synthetic peptide of human CHEK1

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: Oct-50; ELISA: 5000-10000


种属反应性: Rabbit 克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification 种属反应性: Human, Mouse, Rat


成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Epigenetics and Nuclear Signaling, Cancer


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 221730 (CHEK1 Antibody) at a dilution of 1/20 (Cytoplasm).



In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the synthetic peptide and then with 221730(Anti-CHEKI Antibody) at dilution 1/20.



The image on the left is immunohistochemistry of paraffinembedded Human ovarian cancer tissue using 221730(Anti-CHEKI Antibody) at a dilution of 1/20.



In comparision with the IHC on the left, the same paraffin-embedded Human ovarian cancer tissue is first treated with synthetic peptide and then with D263449(Anti-CHEKI Antibody) at dilution 1/20.



## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010